Antitumor effects of vaccination with dendritic cells transfected with modified receptor for hyaluronan-mediated motility mRNA in a mouse glioma model

Journal of Neurosurgery

Volumn 106, Issue 4, 2007, Pages 638-645

  Amano, Takayuki ^a   Kajiwara, Koji ^a   Yoshikawa, Koichi ^a   Morioka, Jun ^a   Nomura, Sadahiro ^a   Fujisawa, Hirosuke ^a   Kato, Shoichi ^a   Fujii, Masami ^a   Fukui, Mikiko ^a   Hinoda, Yuji ^a   Suzuki, Michiyasu ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Dendritic cell; Glioma; Mouse; mRNA; Receptor for hyaluronan mediated motility; Vaccination therapy

Indexed keywords

ANTIGEN; HYALURONIC ACID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; RECEPTOR FOR HYALURONAN MEDIATED MOTILITY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; GENETIC TRANSFECTION; GLIOMA; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION;

ANIMALS; ANTIGENS, CD44; BRAIN NEOPLASMS; CANCER VACCINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX PROTEINS; GENES, MHC CLASS II; GLIOMA; MALE; MICE; MICE, INBRED C57BL; RNA TRANSPORT; RNA, MESSENGER; TRANSFECTION;

EID: 34047204590     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2007.106.4.638     Document Type: Article

References (46)

1. Akasaki Y, Kikuchi T, Homma S, Abe T, Kofe D, Ohno T: Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother 24:106-113, 2001
2. Akiyama Y, Jung S, Salhia B, Lee S, Hubbard S, Taylor M, et al: Hyaluronate receptors mediating glioma cell migration and proliferation. J Neurooncol 53:115-127, 2001
3. Aoki H, Mizuno M, Natsume A, Tsugawa T, Tsujimura K, Takahashi T, et al: Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 50:463-468, 2001
4. Babon A, Almunia C, Boccaccio C, Beaumelle B, Gelb MH, Menez A, et al: Cross-presentation of a CMV pp65 epitope by human dendritic cells using bee venom PLA2 as a membrane-binding vector. FEBS Lett 579:1658-1664, 2005
5. Barratt-Boyes SM, Watkins SC, Finn OJ: In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. J Immunol 158:4543-4547, 1997
6. Cao H, Agrawal D, Kushner N, Touzjian N, Essex M, Lu Y: Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol. J Infect Dis 185:244-251, 2002
7. De Vleeschouwer S, Arredouani M, Ade M, Cadot P, Vermassen E, Ceuppens JL, et al: Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells. Cancer Immunol Immunother 54:372-382, 2005
8. Ehtesham M, Kabos P, Gutierrez MAR, Samoto K, Black KL, Yu JS: Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J Immunother 26:107-116, 2003
9. Fecci PE, Sampson JH: Clinical immunotherapy for brain tumors. Neuroimaging Clin N Am 12:641-664, 2002
10. Frauwirth K, Shastri N: Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains. Immunology 102:405-415, 2001
11. + T cells. Cancer Immunol Immunother 55:538-546, 2006
12. Hall CL, Yang B, Yang X, Zhang S, Turley M, Samuel S, et al: Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell 82:19-26, 1995
13. Hall WA: Extending survival in gliomas: surgical resection or immunotherapy? Surg Neurol 61:145-148, 2004
14. Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, et al: Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50:158-166, 2002
15. Hofmann M, Fieber C, Assmann V, Gottlicher M, Sleeman J, Plug R, et al: Identification of IHABP, a 95 kDa intracellular hyaluronate binding protein. J Cell Sci 111:1673-1684, 1998
16. Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M: A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22:613-621, 2002
17. Kerblat I, Tongiani-Dahshan S, Aude-Garcia C, Villiers M, Drouet C, Marche PN: Tetanus toxin L chain is processed by major histocompatibility complex class I and class II pathways and recognized CD8+ or CD4+ T lymphocytes. Immunology 100:178-184, 2000
18. Kobayashi T, Yamanaka R, Homma J, Tsuchiya N, Yajima N, Yoshida S, et al: Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother 52:632-637, 2003
19. Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill AV, McMichael AJ: Rapid effector function in CD8+ memory T cells. J Exp Med 186:859-865, 1997
20. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, et al: Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90:1115-1124, 1999
21. Line A, Slucka Z, Stengrevics A, Silina K, Li G, Rees RC: Characterisation of tumor-associated antigens in colon cancer. Cancer Immunol Immunother 51:574-582, 2002
22. Marras C, Mendola C, Legnani FG, DiMeco F: Immunotherapy and biological modifiers for the treatment of malignant brain tumors. Curr Opin Oncol 15:204-208, 2003
23. Maxwell CA, Keats JJ, Crainie M, Sun X, Yen T, Shibuya E, et al: RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell 14:2262-2276, 2003
24. Mitchell DA, Nair SK: RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 106:1065-1069, 2000
25. Morioka J, Kajiwara K, Yoshikawa K, Ideguchi M, Uchida T, Ohmoto Y, et al: Adenovirus-mediated gene transfer of B7.1 induces immunological anti-tumor effects in a murine brain tumor. J Neurooncol 60:13-23, 2002
26. Morioka J, Kajiwara K, Yoshikawa K, Ideguchi M, Uchida T, Suzuki M: Vaccine therapy for murine glioma using tumor cells genetically modified to express B7.1. Neurosurgery 54:182-190, 2004
27. Neild A, Murata T, Roy CR: Processing and major histocompatibility complex class II presentation of Legionella pneumophila antigens by infected macrophages. Infect Immun 73:2336-2343, 2005
28. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, et al: Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170:4905-4913, 2003
29. Ohkuma S, Poole B: Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A 75:3327-3331, 1978
30. Orange DE, Jegathesan M, Blachere NE, Frank MO, Scher HI, Albert ML, et al: Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy. Prostate Cancer Prostatic Dis 7:63-72, 2004
31. Parajuli P, Sloan AE: Dendritic cell-based immunotherapy of malignant gliomas. Cancer Invest 22:405-416, 2004
32. Ponsaerts P, Van Tendeloo VF, Berneman ZN: Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol 134:378-384, 2003
33. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T: Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 26:109-113, 2000
34. Saito R, Mizuno M, Nakahara N, Tsuno T, Kumabe T, Yoshimoto T, et al: Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-β gene therapy for malignant glioma in an experimental mouse intracranial glioma. Int J Cancer 111:777-782, 2004
35. Schuler-Thurner BS, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, et al: Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279-1288, 2002
36. Shedlock DJ, Weiner DB: DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 68:793-806, 2000
37. Sioud M, Sorensen D: Generation of an effective anti-tumor immunity after immunization with xenogeneic antigens. Eur J Immunol 33:38-45, 2003
38. Takagi Y, Kikuchi T, Niimura M, Ohno T: Effects of glucocorticoids on antitumor effects of immunizations with fusions of dendritic and tumor cells. Anticancer Res 23:2553-2558, 2003
39. Tolg C, Poon R, Fodde R, Turley EA, Alman BA: Genetic deletion of receptor for hyaluronan-mediated motility (Rhamm) attenuates the formation of aggressive fibromatosis (desmoid tumor). Oncogene 22:6873-6882, 2003
40. Van Meir EG, Bellail A, Phuphanich S: Emerging molecular therapies for brain tumors. Semin Oncol 31 (4 Suppl):38-46, 2004
41. Yamanaka R, Yajima N, Tsuchiya N, Honma J, Tanaka R, Ramsey J, et al: Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki Forest virus-mediated tumor complementary DNA. J Neurosurg 97:1184-1190, 2002
42. Yamanaka R, Zullo SA, Ramsey J, Yajima N, Tsuchiya N, Tanaka R, et al: Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J Neurosurg 97:611-618, 2002
43. Yamanaka R, Zullo SA, Tanaka R, Blaese M, Xanthopoulos KG: Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki Forest virus-mediated complementary DNA. J Neurosurg 94:474-481, 2001
44. Yang T, Witham TF, Villa L, Erff M, Attanucci J, Watkins S, et al: Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res 62:2583-2591, 2002
45. Yoshikawa K, Kajiwara K, Ideguchi M, Uchida T, Ito H: Immune gene therapy of experimental mouse brain tumor with adenovirus-mediated gene transfer of murine interleukin-4. Cancer Immunol Immunother 49:23-33, 2000
46. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842-847, 2001